Methyltransferase-like 3 (METTL3) inhibition potentiates anti-tumor immunity: a novel strategy for improving anti-PD1 therapy [0.03%]
甲基转移酶样蛋白3(METTL3)抑制增强抗肿瘤免疫：提高抗PD1治疗效果的新策略
Anna Brichkina,Roman Suezov,Magdalena Huber
Anna Brichkina
Targeting epigenetic and posttranslational modifications regulating ferroptosis for the treatment of diseases [0.03%]
靶向表观遗传和蛋白质翻译后修饰以调节铁死亡治疗疾病
Yumin Wang,Jing Hu,Shuang Wu et al.
Yumin Wang et al.
Ferroptosis, a unique modality of cell death with mechanistic and morphological differences from other cell death modes, plays a pivotal role in regulating tumorigenesis and offers a new opportunity for modulating anticancer drug resistance...
Antigen-induced chimeric antigen receptor multimerization amplifies on-tumor cytotoxicity [0.03%]
抗原诱导的嵌合抗原受体多聚化可增强对肿瘤细胞的毒性作用
Yan Sun,Xiu-Na Yang,Shuang-Shuang Yang et al.
Yan Sun et al.
Ligand-induced receptor dimerization or oligomerization is a widespread mechanism for ensuring communication specificity, safeguarding receptor activation, and facilitating amplification of signal transduction across the cellular membrane. ...
Christopher C Udoye,Rudolf A Manz
Christopher C Udoye
Non-coding RNAs expression in SARS-CoV-2 infection: pathogenesis, clinical significance, and therapeutic targets [0.03%]
SARS-CoV-2感染中的非编码RNA表达：发病机制、临床意义和治疗靶点
Xiaoxing Liu,Wandi Xiong,Maosen Ye et al.
Xiaoxing Liu et al.
The coronavirus disease 2019 (COVID-19) pandemic has been looming globally for three years, yet the diagnostic and treatment methods for COVID-19 are still undergoing extensive exploration, which holds paramount importance in mitigating fut...
Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study [0.03%]
基于PD-L1表达的纳武单抗联合或不联合含铂双药化疗作为可切除NSCLC的新辅助治疗：一项多中心开放性II期研究（CTONG1804）
Si-Yang Liu,Song Dong,Xue-Ning Yang et al.
Si-Yang Liu et al.
This prospective multicenter phase II study evaluated the clinical efficacy of neoadjuvant nivolumab-exclusive (N) and nivolumab-chemotherapy (N/C) combinations based on PD-L1 expression. Eligible patients exhibited resectable clinical stag...
Tau in the pancreas: understanding the link between type 2 diabetes mellitus and Alzheimer's disease [0.03%]
胰腺中的tau蛋白：2型糖尿病与阿尔茨海默病之间联系的理解
Wenlu Li,Steffen Tiedt,Eng H Lo
Wenlu Li
Gut liver brain axis in diseases: the implications for therapeutic interventions [0.03%]
肠道-肝脏-大脑轴在疾病中的作用：对治疗干预的启示
Mengyao Yan,Shuli Man,Benyue Sun et al.
Mengyao Yan et al.
Gut-liver-brain axis is a three-way highway of information interaction system among the gastrointestinal tract, liver, and nervous systems. In the past few decades, breakthrough progress has been made in the gut liver brain axis, mainly thr...
Managing type 2 diabetes: targeting a microbial enzyme as a novel treatment option [0.03%]
管理2型糖尿病：以靶向微生物酶作为新的治疗选择
Anikó Keller-Pintér,Tamás Korcsmáros,Tibor Vellai
Anikó Keller-Pintér
Going only half the way: cell cycle exit after the G1 restriction point [0.03%]
只走了一半路程：G1限制点后的细胞周期退出
Lisa Müller,Tony Gutschner,Mechthild Hatzfeld
Lisa Müller